Zoetis shares fell 2.2% to $74.40 at the latest close. The filing itself highlighted diluted EPS, which rose to $1.65 for the three months ended June 30, 2026, even though the business sold roughly the same amount as a year earlier.
That per-share improvement came with a different backdrop. Revenue slipped 0.2%, net income fell 4.8%, and net margin declined to 28.0% from 29.3%. The share count dropped 6.2%, which was enough to lift EPS while the underlying profit line moved the other way.
Zoetis says the pressure came from what it sold and foreign exchange. The company also points to pricing and lower manufacturing costs as offsets, but those did not keep margin from narrowing.
The clearest explanation is in the company’s discussion of revenue and margin:
"The increase was primarily a result of: unfavorable product mix; and unfavorable foreign exchange, partially offset by: favorable manufacturing and other costs; and price increases."
Zoetis, 10-Q filed Aug. 6, 2026
In plain English, pricing helped, but the mix of products and currency translation took more than that back. Flat sales therefore carried less profit.
Zoetis did find some cost relief below that line. SG&A expenses decreased by $22 million, according to the company, with lower compensation-related costs, charitable contributions, certain significant items, and depreciation helping offset foreign exchange and professional fees.
"Three months ended June 30, 2026 vs. three months ended June 30, 2025 SG&A expenses decreased by $22 million, or 4%, in the three months ended June 30, 2026, compared with the three months ended June 30, 2025, primarily as a result of: lower compensation-related costs; lower charitable contributions; lower certain significant items; and lower depreciation expense, partially offset by: unfavorable foreign exchange; and higher professional and consulting expense."
Zoetis, 10-Q filed Aug. 6, 2026
That is why EPS can rise without requiring a stronger operating quarter. Lower expenses and fewer shares provided support, while the net margin moved lower.
The cash picture adds another layer. Capital-spending intensity declined, and free-cash-flow margin improved by 0.5 percentage points. But inventory reached $2.6 billion, up 5.5%, faster than revenue. Zoetis does not disclose the reason for that buildup in the supplied filing detail, so the balance-sheet movement sits alongside the better cash conversion rather than explaining it.
The company’s recent annual record makes the current trade-off easier to place. Revenue reached $9.5B in 2025, but annual growth had slowed to 2.3%. At a P/E of 12.4x, the stock is being discussed against a business with a 28.0% latest three-month net margin, but whose latest three-month sales line was stationary.
The specific unresolved receipt for Zoetis’s next quarterly report is whether inventory growth continues to run ahead of revenue and whether management again identifies product mix and foreign exchange as margin pressures. For now, the trade-off is almost comically clear: fewer shares lifted EPS, while product mix pulled down the margin.
Source: Zoetis 10-Q filed Aug. 6, 2026, for the three months ended June 30, 2026.